Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε4 carrier status

Current Alzheimer Research

Volumn 10, Issue 6, 2013, Pages 654-659

  Malek Ahmadi, Michael ^a   Beach, Thomas ^a   Obradov, Aleksandra ^a   Sue, Lucia ^a   Belden, Christine ^a   Davis, Kathryn ^a   Walker, Douglas G ^a   Lue, Lih Fen ^a   Adem, Abdu ^b   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Alzheimer's disease; ApoE; Diabetes; Insulin resistance; Neuropathology

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; DISEASE ASSOCIATION; EFFECT SIZE; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID;

EID: 84882762220     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990006     Document Type: Article

References (32)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8(2): 131-168 (2012).
2. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15:169-173 (2001).
3. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119-1122 (2003).
4. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States 2. Bethesda, MD: US DHHS, NIH; 2003; Rev ed., 2004.
5. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5: 64-74 (2006).
6. Ott A, Stolk RP, Hofman A, van HF, Grobbee, DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study, Diabetologia 39: 1392-1397 (1996).
7. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: An epidemiological perspective. Eur J Pharmacol 585: 119-129 (2008).
8. Han W, Li C. Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sc 107(15): 6557-6558 (2010).
9. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71: 750-757 (2008).
10. Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, Schmeidler J, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 60(4): 471-475 (2005).
11. Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 1792: 454-469 (2009).
12. Arvanitakis Z, Schneider JA, Wilson RS, Li Y, Arnold SE, Wang Z, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67: 1960-1965 (2006).
13. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 75(13):1195-1202 (2010).
14. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66(3): 315-322 (2009).
15. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54: 3343-3348 (2005).
16. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for insulin resistance in neurodegenerative disease. Proc Natl Acad Sc 101(9): 3100-3105 (2004).
17. Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiat11: 721-736 (2006).
18. Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, et al. Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease. Neurology 66: 1506-1510 (2006).
19. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14: 1015-1022 (2000).
20. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51: 1256-1262 (2002).
21. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 38: 941-946 (2003).
22. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, et al. The Sun Health Research Institute Brain Donation Program: Description and experience, 1987-2007. Cell Tissue Bank 9: 229-245 (2008).
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944 (1984).
24. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18: S1-S2 (1997).
25. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486 (1991).
26. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31(3): 545-548 (1990).
27. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71(3): 365-376 (2011).
28. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE ε4. Arch Neurol 65(1): 89-93 (2008).
29. Matsuzaki T, Sasaski K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease. The Hisayama Study. Neurology 75: 764-770 (2010).
30. Craft S. Insulin resistance syndrome and Alzheimer disease: Pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20: 298-301 (2006).
31. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958 (2005).
32. Beach TG, Maarouf CL, Brooks RG, Shirohi S, Daugs ID, Sue LI, et al. Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's disease. BMC Geriatrics 11: 3 (2011).